Tau Therapeutics is an oncology company repositioning and developing T-type calcium channel inhibitors, including its Interlaced Therapy™ method, to treat solid tumors. Its lead product candidate is mibefradil, being tested sequentially with cytotoxic drugs to amplify chemotherapy effectiveness. The company is conducting a Phase 1b dose-escalation trial through the National Cancer Institute’s Adult Brain Tumor Consortium in recurrent high-grade glioma patients. Proceeds from recent financing will support that Phase 1b trial and development of new therapies and diagnostics across multiple indications. Tau is privately held and based in Charlottesville, VA. The company has raised over $10 million from private investors and received over $12 million in non-dilutive resources in the last six years, and plans to present Phase 1b results in 2013.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2012